-
Product Insights
New![]()
Net Present Value Model: Fusion Pharmaceuticals Inc’s FPI-1434
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Fusion Pharmaceuticals Inc’s FPI-1966
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Fusion Pharmaceuticals Inc’s FPI-1434
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.Drug Operating Profit Model
-
Product Insights
New![]()
Net Present Value Model: Fusion Pharmaceuticals Inc’s FPI-2265
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.Drug Operating Profit Model
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – FPI-2059 in Gastric Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. FPI-2059 in Gastric Cancer Drug Details: IPN-01087 is under development for recurrent head and neck...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – FPI-2059 in Ewing Sarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. FPI-2059 in Ewing Sarcoma Drug Details: IPN-01087 is under development for recurrent head and neck...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – FPI-2059 in Metastatic Colorectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. FPI-2059 in Metastatic Colorectal Cancer Drug Details: IPN-01087 is under development for recurrent head and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – FPI-2059 in Metastatic Prostate Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. FPI-2059 in Metastatic Prostate Cancer Drug Details: IPN-01087 is under development for recurrent head and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – FPI-2059 in Pancreatic Ductal Adenocarcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. FPI-2059 in Pancreatic Ductal Adenocarcinoma Drug Details: IPN-01087 is under development for recurrent head and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – FPI-1434 in Ovarian Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.FPI-1434 in Ovarian Cancer Drug Details:FP1-1434 is under development for the treatment of solid tumors, colorectal...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.